Literature DB >> 8425194

Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.

J W Greiner1, C D Ullmann, C Nieroda, C F Qi, D Eggensperger, S Shimada, S M Steinberg, J Schlom.   

Abstract

The moderately differentiated human colon tumor cell line, HT-29, constitutively expresses low levels of the high molecular weight mucin, tumor-associated glycoprotein 72 (TAG-72), and the M(r) 180,000 carcinoembryonic antigen (CEA) when grown as s.c. tumors in athymic mice. We report that the in vivo administration of gamma-interferon (IFN-gamma) resulted in a time- and dose-dependent increase in both TAG-72 and CEA expression in the HT-29 tumors. Immunohistochemical staining revealed a more homogeneous TAG-72-positive tumor cell population after IFN-gamma. Furthermore, both anti-TAG-72 and anti-CEA monoclonal antibodies (MAbs) showed enhanced localization to the HT-29 tumors in mice treated with IFN-gamma. Using that experimental model, subsequent studies presented evidence showing that the combination of IFN-gamma with 131I-CC49, an anti-TAG-72 MAb, resulted in a statistically significant improvement in therapeutic efficacy when compared with 131I-CC49 alone. For example, treatment with 300 microCi of 131I-CC49 initially suppressed HT-29 tumor growth; however, that reduction in tumor growth was transient as evidenced by the emergence of additional tumor growth at later time points. In contrast, an 8-day treatment with IFN-gamma in combination with 300 microCi 131I-CC49 resulted in sustained suppression of HT-29 tumor growth. Thus, IFN-gamma in vivo can substantially increase the TAG-72 expression in human colon tumor xenografts which leads to an increased tumor localization of anti-TAG-72 MAbs and seems to be responsible for the enhanced antitumor effects when IFN-gamma was combined with 131I-CC49. The results provide further evidence for including a biological response modifier, such as IFN-gamma, which can increase the expression of specific tumor antigens (i.e., TAG-72 and CEA) subsequently leading to a dramatic improvement in the antitumor efficacy of a radionuclide-conjugated MAb.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425194

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.

Authors:  M A Reddish; L Jackson; R R Koganty; D Qiu; W Hong; B M Longenecker
Journal:  Glycoconj J       Date:  1997-08       Impact factor: 2.916

Review 2.  Cancer-associated mucins: role in immune modulation and metastasis.

Authors:  Rakesh Bhatia; Shailendra K Gautam; Andrew Cannon; Christopher Thompson; Bradley R Hall; Abhijit Aithal; Kasturi Banerjee; Maneesh Jain; Joyce C Solheim; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

3.  Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer.

Authors:  D M Mahvi; J A Madsen; P L Witt; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

4.  Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.

Authors:  Lubna Abuqayyas; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-27       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.